Translational paradigms in pharmacology and drug discovery.

The translational sciences represent the core element in enabling and utilizing the output from the biomedical sciences and to improving drug discovery metrics by reducing the attrition rate as compounds move from preclinical research to clinical proof of concept. Key to understanding the basis of disease causality and to developing therapeutics is an ability to accurately diagnose the disease and to identify and develop safe and effective therapeutics for its treatment. The former requires validated biomarkers and the latter, qualified targets. Progress has been hampered by semantic issues, specifically those that define the end product, and by scientific issues that include data reliability, an overt reductionistic cultural focus and a lack of hierarchically integrated data gathering and systematic analysis. A necessary framework for these activities is represented by the discipline of pharmacology, efforts and training in which require recognition and revitalization.

[1]  A. Tanay,et al.  Single cell Hi-C reveals cell-to-cell variability in chromosome structure , 2013, Nature.

[2]  Kathryn Moynihan Ramsey,et al.  Circadian rhythms, sleep, and metabolism. , 2011, The Journal of clinical investigation.

[3]  S. Vilar,et al.  High-Throughput Methods for Combinatorial Drug Discovery , 2013, Science Translational Medicine.

[4]  C. Plass,et al.  The evolving epigenome. , 2013, Human molecular genetics.

[5]  Georgina M. Mace,et al.  Distorted Views of Biodiversity: Spatial and Temporal Bias in Species Occurrence Data , 2010, PLoS biology.

[6]  H. Kubinyi Drug research: myths, hype and reality , 2003, Nature Reviews Drug Discovery.

[7]  D. Sackett Bias in analytic research. , 1979, Journal of chronic diseases.

[8]  P. Hopkins Familial hypercholesterolemia--improving treatment and meeting guidelines. , 2003, International journal of cardiology.

[9]  M. Williams,et al.  Challenges in the Search for Drugs to Treat Central Nervous System Disorders , 2009, Journal of Pharmacology and Experimental Therapeutics.

[10]  Chun Liu,et al.  Social Influence Bias : A Randomized Experiment , 2014 .

[11]  P. Sandercock,et al.  Comparison of treatment effects between animal experiments and clinical trials: systematic review , 2006, BMJ : British Medical Journal.

[12]  Hans-Christoph Diener,et al.  NXY-059 for the treatment of acute ischemic stroke. , 2007, The New England journal of medicine.

[13]  Michael Williams,et al.  Replicated, replicable and relevant-target engagement and pharmacological experimentation in the 21st century. , 2014, Biochemical pharmacology.

[14]  K. Eggan,et al.  Modeling human disease with pluripotent stem cells: from genome association to function. , 2013, Cell stem cell.

[15]  Jean-Pierre Gillet,et al.  Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance , 2011, Proceedings of the National Academy of Sciences.

[16]  D. Pisetsky,et al.  DNA microarrays: boundless technology or bound by technology? Guidelines for studies using microarray technology. , 2002, Arthritis and rheumatism.

[17]  D. Light,et al.  Demythologizing the high costs of pharmaceutical research , 2011 .

[18]  Gene W. Yeo,et al.  Long pre-mRNA depletion and RNA missplicing contribute to neuronal vulnerability from loss of TDP-43 , 2011, Nature Neuroscience.

[19]  Mathias Jucker,et al.  The benefits and limitations of animal models for translational research in neurodegenerative diseases , 2010, Nature Medicine.

[20]  Data production leads,et al.  An integrated encyclopedia of DNA elements in the human genome , 2012 .

[21]  B. Munos Lessons from 60 years of pharmaceutical innovation , 2009, Nature Reviews Drug Discovery.

[22]  Kenneth M. Yamada,et al.  What's in a picture? The temptation of image manipulation , 2004, The Journal of cell biology.

[23]  W. Cookson,et al.  Genetic and genomic approaches to asthma: new insights for the origins , 2012, Current opinion in pulmonary medicine.

[24]  David F. Horrobin,et al.  Modern biomedical research: an internally self-consistent universe with little contact with medical reality? , 2003, Nature Reviews Drug Discovery.

[25]  Sheng Ding,et al.  TARGET VALIDATION IN CHEMOGENOMICS , 2007 .

[26]  J. Moreau,et al.  Rodent models of insomnia: A review of experimental procedures that induce sleep disturbances , 2009, Neuroscience & Biobehavioral Reviews.

[27]  J. Grotta,et al.  NXY-059 for the Treatment of Acute Stroke: Pooled Analysis of the SAINT I and II Trials , 2008, Stroke.

[28]  P. Bath,et al.  Effects of NXY‐059 in experimental stroke: an individual animal meta‐analysis , 2009, British journal of pharmacology.

[29]  D. Swinney,et al.  How were new medicines discovered? , 2011, Nature Reviews Drug Discovery.

[30]  David Julius,et al.  Identification of the platelet ADP receptor targeted by antithrombotic drugs , 2001, Nature.

[31]  Elena Cattaneo,et al.  Molecular mechanisms and potential therapeutical targets in Huntington's disease. , 2010, Physiological reviews.

[32]  A. Casadevall,et al.  Reforming Science: Methodological and Cultural Reforms , 2011, Infection and Immunity.

[33]  A. Towse,et al.  The R&D Cost of a New Medicine , 2012 .

[34]  J. Black Pharmacology: analysis and exploration. , 1986, British medical journal.

[35]  Stephen B. Johnson,et al.  Central challenges facing the national clinical research enterprise. , 2003, JAMA.

[36]  D. Fanelli How Many Scientists Fabricate and Falsify Research? A Systematic Review and Meta-Analysis of Survey Data , 2009, PloS one.

[37]  N. Patterson,et al.  Using Extended Genealogy to Estimate Components of Heritability for 23 Quantitative and Dichotomous Traits , 2013, PLoS genetics.

[38]  S. Lazic,et al.  A call for transparent reporting to optimize the predictive value of preclinical research , 2012, Nature.

[39]  Invited commentary-Genetic prediction for common diseases. , 2012, Archives of internal medicine.

[40]  H. Moses,et al.  Biomedical research and health advances. , 2011, The New England journal of medicine.

[41]  L. Menand The marketplace of ideas , 2010 .

[42]  Elaine Romanelli,et al.  Organizational Legacy and the Internal Dynamics of Clusters: The U.S. Human Biotherapeutics Industry, 1976–2002 , 2013 .

[43]  Thomas Steckler,et al.  Touching on translation , 2013, Cell and Tissue Research.

[44]  T. Kenakin,et al.  Defining and characterizing drug/compound function. , 2014, Biochemical pharmacology.

[45]  Albert Gough,et al.  High-Content Screening: A New Approach to Easing Key Bottlenecks in the Drug Discovery Process , 1997 .

[46]  Steven T. Corneliussen Steven T. Corneliussen Wall Street Journal front page: "Mistakes in Scientific Studies Surge" , 2011 .

[47]  A. Nagy,et al.  EMBRYONIC STEM CELLS / INDUCED PLURIPOTENT STEM CELLS Concise Review : Embryonic Stem Cells Versus Induced Pluripotent Stem Cells : The Game Is On , 2011 .

[48]  Thomas A Trikalinos,et al.  Early extreme contradictory estimates may appear in published research: the Proteus phenomenon in molecular genetics research and randomized trials. , 2005, Journal of clinical epidemiology.

[49]  A. Brazma,et al.  Reuse of public genome-wide gene expression data , 2012, Nature Reviews Genetics.

[50]  B. Ding,et al.  Mutations in SCN9A, encoding a sodium channel alpha subunit, in patients with primary erythermalgia , 2004, Journal of Medical Genetics.

[51]  D. Howells,et al.  Can Animal Models of Disease Reliably Inform Human Studies? , 2010, PLoS medicine.

[52]  P. Almgren,et al.  Genetic polymorphisms for estimating risk of atrial fibrillation in the general population: a prospective study. , 2012, Archives of internal medicine.

[53]  Julio D. Duarte Epigenetics Primer: Why the Clinician Should Care About Epigenetics , 2013, Pharmacotherapy.

[54]  J. Maffrand,et al.  Broad spectrum anti-platelet activity of ticlopidine and PCR 4099 involves the suppression of the effects of released ADP. , 1987, Thrombosis research.

[55]  Michael Williams Commentary: genome-based CNS drug discovery: D-amino acid oxidase (DAAO) as a novel target for antipsychotic medications: progress and challenges. , 2009, Biochemical pharmacology.

[56]  M. Fraga,et al.  Epigenetics and the environment: emerging patterns and implications , 2012, Nature Reviews Genetics.

[57]  Terrence P. Kenakin,et al.  A Pharmacology Primer: Theory, Application and Methods , 2004 .

[58]  M. Mathews,et al.  An Interview with , 2009 .

[59]  A. Balmain,et al.  Genetic variants of Tgfb1 act as context-dependent modifiers of mouse skin tumor susceptibility. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[60]  D. Goldstein,et al.  Sequencing studies in human genetics: design and interpretation , 2013, Nature Reviews Genetics.

[61]  John P A Ioannidis,et al.  An epidemic of false claims. Competition and conflicts of interest distort too many medical findings. , 2011, Scientific American.

[62]  Chris Anderson,et al.  Beyond the Sequence , 2015 .

[63]  J. Dungan,et al.  Carrier Testing for Severe Childhood Recessive Diseases by Next-Generation Sequencing , 2012 .

[64]  D. E. McKinney Saw palmetto for benign prostatic hyperplasia. , 1999, JAMA.

[65]  A. Young,et al.  A polymorphic DNA marker genetically linked to Huntington's disease , 1983, Nature.

[66]  E. Spack,et al.  The basics of preclinical drug development for neurodegenerative disease indications , 2009, BMC neurology.

[67]  Khusru Asadullah,et al.  What makes a good drug target? , 2012, Drug discovery today.

[68]  Meredith Wadman,et al.  NIH mulls rules for validating key results , 2013, Nature.

[69]  S. Rees,et al.  Principles of early drug discovery , 2011, British journal of pharmacology.

[70]  Toshihiro Tanaka The International HapMap Project , 2003, Nature.

[71]  F. Marincola,et al.  Expanding the perspective of translational medicine: the value of observational data , 2012, Journal of Translational Medicine.

[72]  E. Nimmo,et al.  Beyond Gene Discovery in Inflammatory Bowel Disease: The Emerging Role of Epigenetics , 2013, Gastroenterology.

[73]  P. Leeson,et al.  The influence of drug-like concepts on decision-making in medicinal chemistry , 2007, Nature Reviews Drug Discovery.

[74]  K. Mullane,et al.  Animal models of asthma: reprise or reboot? , 2014, Biochemical pharmacology.

[75]  S. Bagshaw,et al.  Novel biomarkers of AKI: the challenges of progress 'Amid the noise and the haste'. , 2013, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[76]  J. Ott,et al.  Complement Factor H Polymorphism in Age-Related Macular Degeneration , 2005, Science.

[77]  T Takahashi,et al.  Traditional Chinese Medicine and Kampo: A Review from the Distant past for the Future , 2006, The Journal of international medical research.

[78]  N. H. Rubin,et al.  Circadian rhythm. , 1983, The Journal of investigative dermatology.

[79]  Philip Cooke,et al.  Regional Innovation Systems: General Findings and Some New Evidence from Biotechnology Clusters , 2002 .

[80]  R. Steen Retractions in the scientific literature: is the incidence of research fraud increasing? , 2010, Journal of Medical Ethics.

[81]  Changyu Shen,et al.  Survival and CTG repeat expansion in adults with myotonic dystrophy type 1 , 2011, Muscle & nerve.

[82]  Martin Wehling,et al.  Translatability scoring in drug development: eight case studies , 2012, Journal of Translational Medicine.

[83]  T. Willson,et al.  The importance of chronobiology to drug discovery , 2012, Expert opinion on drug discovery.

[84]  Mark S Butler,et al.  The role of natural product chemistry in drug discovery. , 2004, Journal of natural products.

[85]  E. Lander,et al.  The mystery of missing heritability: Genetic interactions create phantom heritability , 2012, Proceedings of the National Academy of Sciences.

[86]  Jan van Gijn,et al.  Acute Ischemic Stroke , 2007 .

[87]  Jean Golding,et al.  The search for genenotype/phenotype associations and the phenome scan. , 2005, Paediatric and perinatal epidemiology.

[88]  G. Malhi,et al.  Chronobiology of mood disorders , 2013, Acta psychiatrica Scandinavica. Supplementum.

[89]  P. Bhargava,et al.  Animal models of sleep disorders. , 2013, Comparative medicine.

[90]  Péter Kakuk,et al.  The Legacy of the Hwang Case: Research Misconduct in Biosciences , 2009, Sci. Eng. Ethics.

[91]  J. Trojanowski,et al.  Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people. , 2010, Archives of neurology.

[92]  T. Misteli Beyond the Sequence: Cellular Organization of Genome Function , 2011 .

[93]  K. Hochedlinger,et al.  A variant CRISPR-Cas9 system adds versatility to genome engineering , 2013, Proceedings of the National Academy of Sciences.

[94]  B. Deer,et al.  How the case against the MMR vaccine was fixed , 2011, BMJ : British Medical Journal.

[95]  Paul Morgan,et al.  Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving Phase II survival. , 2012, Drug discovery today.

[96]  W. Pullman,et al.  From bench to clinic and back: Perspective on the 1st IQPC Translational Research conference , 2004, Journal of Translational Medicine.

[97]  A. Mandavilli Peer review: Trial by Twitter , 2011, Nature.

[98]  John P A Ioannidis,et al.  Excess significance bias in the literature on brain volume abnormalities. , 2011, Archives of general psychiatry.

[99]  Thanos Athanasiou,et al.  How to Read a Paper , 2010 .

[100]  M. Danhof,et al.  Commentary: "A systems view on the future of medicine: inspiration from Chinese medicine?". , 2009, Journal of ethnopharmacology.

[101]  P. Sandercock,et al.  Where is the evidence that animal research benefits humans? , 2004, BMJ : British Medical Journal.

[102]  J. Vederas,et al.  Drug Discovery and Natural Products: End of an Era or an Endless Frontier? , 2009, Science.

[103]  M. Carskadon,et al.  Circadian rhythm sleep disorders: part I, basic principles, shift work and jet lag disorders. An American Academy of Sleep Medicine review. , 2007, Sleep.

[104]  London,et al.  The Rise and Fall of Modern Medicine , 2000 .

[105]  D. Howells,et al.  Publication Bias in Reports of Animal Stroke Studies Leads to Major Overstatement of Efficacy , 2010, PLoS biology.

[106]  Alexander Schuhmacher,et al.  How to create innovation by building the translation bridge from basic research into medicinal drugs: an industrial perspective , 2012, Human Genomics.

[107]  E. Dorsey,et al.  Financing of U.S. Biomedical Research and New Drug Approvals across Therapeutic Areas , 2009, PloS one.

[108]  J. Holdway,et al.  In vivo monitoring of cardiomyocyte proliferation to identify chemical modifiers of heart regeneration , 2013, Development.

[109]  Arturo Casadevall,et al.  Why Has the Number of Scientific Retractions Increased? , 2013, PloS one.

[110]  F. Zitman,et al.  Antipsychotic polypharmacy in psychotic disorders: a critical review of neurobiology, efficacy, tolerability and cost effectiveness , 2013, Journal of psychopharmacology.

[111]  J. Couzin-Frankel Cancer research. As questions grow, Duke halts trials, launches investigation. , 2010, Science.

[112]  Michael R. Hayden,et al.  Hunting human disease genes: lessons from the past, challenges for the future , 2013, Human Genetics.

[113]  B. Pulverer Science publishing: How to stop plagiarism , 2012, Nature.

[114]  J. Grimshaw,et al.  Threats to Validity in the Design and Conduct of Preclinical Efficacy Studies: A Systematic Review of Guidelines for In Vivo Animal Experiments , 2013, PLoS medicine.

[115]  Michael A Fischbach,et al.  New antibiotics from bacterial natural products , 2006, Nature Biotechnology.

[116]  Kelly Rae Chi Revolution dawning in cardiotoxicity testing , 2013, Nature Reviews Drug Discovery.

[117]  Christine Van Broeckhoven,et al.  Genetic insights in Alzheimer's disease , 2013, The Lancet Neurology.

[118]  B. Aggarwal,et al.  Pharmacological basis for the role of curcumin in chronic diseases: an age-old spice with modern targets. , 2009, Trends in pharmacological sciences.

[119]  S. Vedula,et al.  Restoring invisible and abandoned trials: a call for people to publish the findings , 2013, The BMJ.

[120]  T. Cremer,et al.  Chromosome territories, nuclear architecture and gene regulation in mammalian cells , 2001, Nature Reviews Genetics.

[121]  G. Donnan,et al.  1,026 Experimental treatments in acute stroke , 2006, Annals of neurology.

[122]  Cassidy R. Sugimoto,et al.  Bias in peer review , 2013, J. Assoc. Inf. Sci. Technol..

[123]  B. Roth,et al.  Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia , 2004, Nature Reviews Drug Discovery.

[124]  Brian A. Nosek,et al.  Power failure: why small sample size undermines the reliability of neuroscience , 2013, Nature Reviews Neuroscience.

[125]  B. Ruggeri,et al.  Animal models of human disease: challenges in enabling translation. , 2014, Biochemical pharmacology.

[126]  Fatih Ozsolak,et al.  RNA sequencing: advances, challenges and opportunities , 2011, Nature Reviews Genetics.

[127]  Ulrich Dirnagl,et al.  Reprint: Good Laboratory Practice: Preventing Introduction of Bias at the Bench , 2009, Stroke.

[128]  Donald F. Klein,et al.  The loss of serendipity in psychopharmacology. , 2008, JAMA.

[129]  J. Ioannidis Extrapolating from Animals to Humans , 2012, Science Translational Medicine.

[130]  Steven J. Schrodi,et al.  A PheWAS approach in studying HLA-DRB1*1501 , 2013, Genes and Immunity.

[131]  S. Woolf The meaning of translational research and why it matters. , 2008, JAMA.

[132]  B. E. Foreman,et al.  Predicting the physiological relevance of in vitro cancer preventive activities of phytochemicals , 2007, Acta Pharmacologica Sinica.

[133]  J. Ioannidis,et al.  Evaluation of Excess Significance Bias in Animal Studies of Neurological Diseases , 2013, PLoS biology.

[134]  E. Mardis Next-generation sequencing platforms. , 2013, Annual review of analytical chemistry.

[135]  D. Newman,et al.  Natural products as sources of new drugs over the last 25 years. , 2007, Journal of natural products.

[136]  Michael J Marino,et al.  The use and misuse of statistical methodologies in pharmacology research. , 2014, Biochemical pharmacology.

[137]  F. Prinz,et al.  Believe it or not: how much can we rely on published data on potential drug targets? , 2011, Nature Reviews Drug Discovery.

[138]  Vivien Marx,et al.  Next-generation sequencing: The genome jigsaw , 2013, Nature.

[139]  H. Wortelboer,et al.  Combined Analysis of Pharmacokinetic and Efficacy Data of Preclinical Studies with Statins Markedly Improves Translation of Drug Efficacy to Human Trials , 2013, The Journal of Pharmacology and Experimental Therapeutics.

[140]  L. D. de Windt,et al.  Regulation of fetal gene expression in heart failure. , 2013, Biochimica et biophysica acta.

[141]  S. Finkbeiner,et al.  Modeling Huntington's disease with induced pluripotent stem cells , 2013, Molecular and Cellular Neuroscience.

[142]  G. Nepom,et al.  Animal models of human type 1 diabetes , 2009, Nature Immunology.

[143]  Rae Silver,et al.  Orchestrating time: arrangements of the brain circadian clock , 2005, Trends in Neurosciences.

[144]  S. Enna,et al.  Defining the role of pharmacology in the emerging world of translational research. , 2009, Advances in pharmacology.

[145]  R. Barker,et al.  Parkinson's Disease in a Dish: What Patient Specific-Reprogrammed Somatic Cells Can Tell Us about Parkinson's Disease, If Anything? , 2012, Stem cells international.

[146]  M. Rosenblatt How academia and the pharmaceutical industry can work together: the president's lecture, annual meeting of the American Thoracic Society, San Francisco, California. , 2013, Annals of the American Thoracic Society.

[147]  M. Genovese Inhibition of p38: has the fat lady sung? , 2009, Arthritis and rheumatism.

[148]  G. FitzGerald,et al.  Historical lessons in translational medicine: cyclooxygenase inhibition and P2Y12 antagonism. , 2013, Circulation research.

[149]  Gert-Jan Hospers,et al.  The New Economic Geography of Old Industrial Regions: Universities as Global — Local Pipelines , 2007 .

[150]  A. Feinberg,et al.  Higher order chromatin organization in cancer. , 2013, Seminars in cancer biology.

[151]  Gene W. Yeo,et al.  Genome-Wide Approaches to Dissect the Roles of RNA Binding Proteins in Translational Control: Implications for Neurological Diseases , 2012, Front. Neurosci..

[152]  M. Fisher,et al.  NXY-059 for the treatment of stroke. , 2007, The New England journal of medicine.

[153]  G. Marek,et al.  Developing predictive CSF biomarkers-a challenge critical to success in Alzheimer's disease and neuropsychiatric translational medicine. , 2011, Biochemical pharmacology.

[154]  Marijn T. M. van Jaarsveld,et al.  Defining Genetic Factors That Modulate Intergenerational CAG Repeat Instability in Drosophila melanogaster , 2011, Genetics.

[155]  J. Shorter,et al.  RNA-Binding Proteins in Amyotrophic Lateral Sclerosis and Neurodegeneration , 2012, Neurology research international.

[156]  Manish S. Shah,et al.  A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes , 1993, Cell.

[157]  Raymond J Winquist,et al.  The fall and rise of pharmacology--(re-)defining the discipline? , 2014, Biochemical pharmacology.

[158]  Kevin Kim,et al.  A TALEN genome-editing system for generating human stem cell-based disease models. , 2013, Cell stem cell.

[159]  Peter Elkind,et al.  Inside Pfizer's palace coup. Did CEO Jeff Kindler get pushed out because he was shaking up the dysfunctional pharmaceutical giant--or because he was an ineffective leader? , 2011, Fortune.

[160]  R. Cancedda,et al.  An intronic ncRNA-dependent regulation of SORL1 expression affecting Aβ formation is upregulated in post-mortem Alzheimer's disease brain samples , 2012, Disease Models & Mechanisms.

[161]  Fred H. Gage,et al.  Induced pluripotent stem cells: the new patient? , 2012, Nature Reviews Molecular Cell Biology.

[162]  S. Yamanaka Induced pluripotent stem cells: past, present, and future. , 2012, Cell stem cell.

[163]  C. Ball,et al.  Repeatability of published microarray gene expression analyses , 2009, Nature Genetics.

[164]  Thomas Hankemeier,et al.  Systems biology-based diagnostic principles as pillars of the bridge between Chinese and Western medicine. , 2010, Planta medica.

[165]  Calliope A. Dendrou,et al.  TNF receptor 1 genetic risk mirrors outcome of anti-TNF therapy in multiple sclerosis , 2012, Nature.

[166]  Peter Imming,et al.  Drugs, their targets and the nature and number of drug targets , 2007, Nature Reviews Drug Discovery.

[167]  H. Calkins,et al.  Studying arrhythmogenic right ventricular dysplasia with patient-specific iPSCs , 2012, Nature.

[168]  R. Gamelli,et al.  Genomic responses in mouse models poorly mimic human inflammatory diseases , 2013, Proceedings of the National Academy of Sciences.

[169]  Hugues Dolgos,et al.  Early integration of pharmacokinetic and dynamic reasoning is essential for optimal development of lead compounds: strategic considerations. , 2009, Drug discovery today.

[170]  D. Bylund,et al.  Quantitative versus qualitative data: the numerical dimensions of drug action. , 2014, Biochemical pharmacology.

[171]  Patricia M. LoRusso,et al.  Phase 0 clinical trials: an answer to drug development stagnation? , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[172]  Teri A. Manolio,et al.  Bringing genome-wide association findings into clinical use , 2013, Nature Reviews Genetics.

[173]  Gonçalo R. Abecasis,et al.  Genetic variants regulating ORMDL3 expression contribute to the risk of childhood asthma , 2007, Nature.

[174]  Shane J. Neph,et al.  Systematic Localization of Common Disease-Associated Variation in Regulatory DNA , 2012, Science.

[175]  James Le Fanu,et al.  The Rise and Fall of Modern Medicine , 1999 .

[176]  Krishna Kodukula,et al.  Biomarkers in pharmacology and drug discovery. , 2014, Biochemical pharmacology.

[177]  E. Maywood,et al.  Circadian clocks: regulators of endocrine and metabolic rhythms. , 2007, The Journal of endocrinology.

[178]  Curtis J Henrich,et al.  Matching the power of high throughput screening to the chemical diversity of natural products. , 2013, Natural product reports.

[179]  John Higgins,et al.  Progressing preclinical drug candidates: strategies on preclinical safety studies and the quest for adequate exposure. , 2012, Drug discovery today.

[180]  M. Kitazawa Circadian Rhythms, Metabolism, and Insulin Sensitivity: Transcriptional Networks in Animal Models , 2013, Current Diabetes Reports.

[181]  David J Newman,et al.  Natural products as sources of new drugs over the 30 years from 1981 to 2010. , 2012, Journal of natural products.

[182]  Youssef L Bennani,et al.  Drug discovery in the next decade: innovation needed ASAP. , 2012, Drug discovery today.

[183]  C. Begley,et al.  Drug development: Raise standards for preclinical cancer research , 2012, Nature.

[184]  F. Lombardo,et al.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. , 2001, Advanced drug delivery reviews.

[185]  Ueli Schibler,et al.  Circadian rhythms: mechanisms and therapeutic implications. , 2007, Annual review of pharmacology and toxicology.

[186]  D. Braff,et al.  The neuropsychiatric translational revolution: still very early and still very challenging. , 2013, JAMA psychiatry.

[187]  Richard Morphy,et al.  Designed Multiple Ligands. An Emerging Drug Discovery Paradigm , 2006 .

[188]  J. Ioannidis Why Science Is Not Necessarily Self-Correcting , 2012, Perspectives on psychological science : a journal of the Association for Psychological Science.

[189]  J. Brooks Why most published research findings are false: Ioannidis JP, Department of Hygiene and Epidemiology, University of Ioannina School of Medicine, Ioannina, Greece , 2008 .

[190]  K. Coombes,et al.  Deriving chemosensitivity from cell lines: Forensic bioinformatics and reproducible research in high-throughput biology , 2009, 1010.1092.

[191]  B. Cravatt,et al.  Determining target engagement in living systems. , 2013, Nature chemical biology.

[192]  D. DeMets,et al.  Data integrity. , 2020, Controlled clinical trials.

[193]  R. Myers,et al.  Quality assessment of the human genome sequence , 2004, Nature.

[194]  Michael P. Snyder,et al.  Extensive genetic variation in somatic human tissues , 2012, Proceedings of the National Academy of Sciences.

[195]  Miles Parkes,et al.  Genetic insights into common pathways and complex relationships among immune-mediated diseases , 2013, Nature Reviews Genetics.

[196]  Birgit Schoeberl,et al.  An expanding role for cell biologists in drug discovery and pharmacology , 2012, Molecular biology of the cell.

[197]  Katriina Aalto-Setälä,et al.  Model for long QT syndrome type 2 using human iPS cells demonstrates arrhythmogenic characteristics in cell culture , 2011, Disease Models & Mechanisms.

[198]  Joost C M Uitdehaag The seven types of drug discovery waste: toward a new lean for the drug industry. , 2011, Drug discovery today.

[199]  B. Ploeger,et al.  The virtue of translational PKPD modeling in drug discovery: selecting the right clinical candidate while sparing animal lives. , 2013, Drug discovery today.

[200]  J. Ioannidis,et al.  Quantifying Selective Reporting and the Proteus Phenomenon for Multiple Datasets with Similar Bias , 2011, PloS one.

[201]  T Misteli,et al.  Protein dynamics: implications for nuclear architecture and gene expression. , 2001, Science.

[202]  Anirban Basu,et al.  A CTSA Agenda to Advance Methods for Comparative Effectiveness Research , 2011, Clinical and translational science.

[203]  Y. Lazebnik Can a biologist fix a radio? — or, what I learned while studying apoptosis , 2004, Biochemistry (Moscow).

[204]  H. Hobbs,et al.  Evidence for a dominant gene that suppresses hypercholesterolemia in a family with defective low density lipoprotein receptors. , 1989, The Journal of clinical investigation.

[205]  U. Dirnagl,et al.  Evidence for the Efficacy of NXY-059 in Experimental Focal Cerebral Ischaemia Is Confounded by Study Quality , 2008, Stroke.

[206]  Laraine T. Zappert,et al.  In the pipeline , 1985 .

[207]  Sydney Brenner,et al.  An interview with... Sydney Brenner. Interview by Errol C. Friedberg. , 2008, Nature reviews. Molecular cell biology.

[208]  Michael Williams,et al.  Productivity Shortfalls in Drug Discovery: Contributions from the Preclinical Sciences? , 2011, Journal of Pharmacology and Experimental Therapeutics.

[209]  J. Loscalzo Irreproducible experimental results: causes, (mis)interpretations, and consequences. , 2012, Circulation.

[210]  P. Clemons,et al.  Target identification and mechanism of action in chemical biology and drug discovery. , 2013, Nature chemical biology.

[211]  Marylyn D. Ritchie,et al.  PheWAS: demonstrating the feasibility of a phenome-wide scan to discover gene–disease associations , 2010, Bioinform..

[212]  P. Marjoram,et al.  Post-GWAS: where next? More samples, more SNPs or more biology? , 2013, Heredity.

[213]  M. Esteller Non-coding RNAs in human disease , 2011, Nature Reviews Genetics.

[214]  Experimental Irreproducibility: Causes, (Mis)interpretations, and Consequences , 2012 .

[215]  K. Blennow,et al.  Use of theragnostic markers to select drugs for phase II/III trials for Alzheimer disease , 2010, Alzheimer's Research & Therapy.

[216]  Ben R. Martin,et al.  Whither research integrity? Plagiarism, self-plagiarism and coercive citation in an age of research assessment , 2013 .

[217]  E. Lander Initial impact of the sequencing of the human genome , 2011, Nature.

[218]  S. Goineau,et al.  Overview of Safety Pharmacology , 2013, Current protocols in pharmacology.

[219]  Karla K Kopec,et al.  Target identification and validation in drug discovery: the role of proteomics. , 2005, Biochemical pharmacology.

[220]  C Kooperberg,et al.  The use of phenome‐wide association studies (PheWAS) for exploration of novel genotype‐phenotype relationships and pleiotropy discovery , 2011, Genetic epidemiology.

[221]  Kennon Heard,et al.  Emergency medicine animal research: does use of randomization and blinding affect the results? , 2003, Academic emergency medicine : official journal of the Society for Academic Emergency Medicine.

[222]  G. Joos,et al.  Targeting interleukin-4 in asthma: lost in translation? , 2012, American journal of respiratory cell and molecular biology.

[223]  D. Altshuler,et al.  Validating therapeutic targets through human genetics , 2013, Nature Reviews Drug Discovery.

[224]  J. Scannell,et al.  Diagnosing the decline in pharmaceutical R&D efficiency , 2012, Nature Reviews Drug Discovery.

[225]  F. Collins,et al.  A vision for the future of genomics research , 2003, Nature.

[226]  M. Rotger,et al.  Pharmacogenomics: What is Next? , 2011, Front. Pharmacol..

[227]  D. Eyding,et al.  Reboxetine for acute treatment of major depression: systematic review and meta-analysis of published and unpublished placebo and selective serotonin reuptake inhibitor controlled trials , 2010, BMJ : British Medical Journal.

[228]  F. Collins Has the revolution arrived? , 2010, Nature.

[229]  A. Casadevall,et al.  Misconduct accounts for the majority of retracted scientific publications , 2012, Proceedings of the National Academy of Sciences.

[230]  W. Busse,et al.  Genome-wide association studies of asthma indicate opposite immunopathogenesis direction from autoimmune diseases. , 2012, The Journal of allergy and clinical immunology.

[231]  Markus Grammel,et al.  Chemical reporters for biological discovery. , 2013, Nature chemical biology.

[232]  D C Swinney,et al.  Phenotypic vs. Target‐Based Drug Discovery for First‐in‐Class Medicines , 2013, Clinical pharmacology and therapeutics.

[233]  M. Ritskes-Hoitinga,et al.  Progress in Using Systematic Reviews of Animal Studies to Improve Translational Research , 2013, PLoS medicine.

[234]  K. Mullane,et al.  Alzheimer's therapeutics: continued clinical failures question the validity of the amyloid hypothesis-but what lies beyond? , 2013, Biochemical pharmacology.

[235]  A. Casadevall,et al.  Reforming Science: Structural Reforms , 2011, Infection and Immunity.

[236]  Mark E Bunnage,et al.  Target validation using chemical probes. , 2013, Nature chemical biology.

[237]  Jacob A. Tennessen,et al.  Evolution and Functional Impact of Rare Coding Variation from Deep Sequencing of Human Exomes , 2012, Science.

[238]  M. Wehling Drug development in the light of translational science: shine or shade? , 2011, Drug discovery today.

[239]  D. Sall,et al.  Modern phenotypic drug discovery is a viable, neoclassic pharma strategy. , 2012, Journal of medicinal chemistry.

[240]  B. Ruggeri,et al.  Animal models of disease: pre-clinical animal models of cancer and their applications and utility in drug discovery. , 2014, Biochemical pharmacology.

[241]  Nicholas Eriksson,et al.  Comparison of Family History and SNPs for Predicting Risk of Complex Disease , 2012, PLoS genetics.

[242]  M. Bracken Why animal studies are often poor predictors of human reactions to exposure , 2009, Journal of the Royal Society of Medicine.

[243]  Arturo Casadevall,et al.  Lost in Translation—Basic Science in the Era of Translational Research , 2009, Infection and Immunity.

[244]  Suzanne K. Linder,et al.  A Survey on Data Reproducibility in Cancer Research Provides Insights into Our Limited Ability to Translate Findings from the Laboratory to the Clinic , 2013, PloS one.

[245]  M. Lyon An Interview With... , 2004, Nature Reviews Genetics.

[246]  K. Mullane,et al.  Translational semantics and infrastructure: another search for the emperor's new clothes? , 2012, Drug discovery today.

[247]  F. Pammolli,et al.  The productivity crisis in pharmaceutical R&D , 2011, Nature Reviews Drug Discovery.

[248]  Andrew Hughes,et al.  Model-based drug discovery: implementation and impact. , 2013, Drug discovery today.

[249]  J. Mehlsen,et al.  The efficacy of St. John's Wort in patients with minor depressive symptoms or dysthymia--a double-blind placebo-controlled study. , 2006, Phytomedicine : international journal of phytotherapy and phytopharmacology.

[250]  T. Tokuyasu,et al.  Epistatic interactions between Tgfb1 and genetic loci, Tgfbm2 and Tgfbm3, determine susceptibility to an asthmatic stimulus , 2012, Proceedings of the National Academy of Sciences.

[251]  P. Mcgonigle Animal models of CNS disorders. , 2014, Biochemical pharmacology.

[252]  Francis Lévi,et al.  Implications of circadian clocks for the rhythmic delivery of cancer therapeutics. , 2007, Advanced drug delivery reviews.

[253]  John P. A. Ioannidis,et al.  An epidemic of false claims. , 2011 .

[254]  J. Weissenbach,et al.  Mutations in PCSK9 cause autosomal dominant hypercholesterolemia , 2003, Nature Genetics.

[255]  W. Eaton,et al.  Epidemiology of schizophrenia: review of findings and myths. , 2007, The Psychiatric clinics of North America.

[256]  How do the top 12 pharmaceutical companies operate safety pharmacology? , 2012, Journal of pharmacological and toxicological methods.

[257]  Marc Vandemeulebroecke,et al.  Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial , 2012, Gut.

[258]  Martin Wehling,et al.  Assessing the translatability of drug projects: what needs to be scored to predict success? , 2009, Nature Reviews Drug Discovery.

[259]  D. Blumenthal,et al.  The benefits of health information technology: a review of the recent literature shows predominantly positive results. , 2011, Health affairs.

[260]  Torsten Kluba,et al.  Genetic correction of a LRRK2 mutation in human iPSCs links parkinsonian neurodegeneration to ERK-dependent changes in gene expression. , 2013, Cell stem cell.

[261]  Federico M Goodsaid,et al.  Strategic paths for biomarker qualification. , 2008, Toxicology.

[262]  U. Dirnagl,et al.  REPRINT: Good Laboratory Practice: Preventing Introduction of Bias at the Bench , 2009, International journal of stroke : official journal of the International Stroke Society.

[263]  I. Cuthill,et al.  Survey of the Quality of Experimental Design, Statistical Analysis and Reporting of Research Using Animals , 2009, PloS one.

[264]  Errol C. Friedberg,et al.  Sydney Brenner , 2008, Nature Reviews Molecular Cell Biology.

[265]  Christopher M. Kirchhoff,et al.  Columbia Accident Investigation Board. Volume 4 , 2003 .

[266]  L. Criswell,et al.  Emerging patterns of genetic overlap across autoimmune disorders , 2012, Genome Medicine.

[267]  R Hill,et al.  NK1 (substance P) receptor antagonists--why are they not analgesic in humans? , 2000, Trends in pharmacological sciences.

[268]  Etienne Weiss,et al.  Therapeutic antibodies: successes, limitations and hopes for the future , 2009, British journal of pharmacology.

[269]  Peter A. Jones,et al.  Epigenetics in human disease and prospects for epigenetic therapy , 2004, Nature.

[270]  F. Godlee,et al.  Wakefield’s article linking MMR vaccine and autism was fraudulent , 2011, BMJ : British Medical Journal.

[271]  Martin Wehling,et al.  Translational medicine: can it really facilitate the transition of research “from bench to bedside”? , 2006, European Journal of Clinical Pharmacology.

[272]  D. Webb Animal models of human disease: inflammation. , 2014, Biochemical pharmacology.

[273]  Robert M. Rydzewski,et al.  Real World Drug Discovery: A Chemist's Guide to Biotech and Pharmaceutical Research , 2008 .

[274]  L. Studer,et al.  Identification of Compounds that Rescue IKBKAP Expression in Familial Dysautonomia-iPS Cells , 2012, Nature Biotechnology.

[275]  J. Lupski Genome Mosaicism—One Human, Multiple Genomes , 2013, Science.

[276]  John P. A. Ioannidis,et al.  This I believe in genetics: discovery can be a nuisance, replication is science, implementation matters , 2013, Front. Genet..

[277]  Jeanette J McCarthy,et al.  Genomic Medicine: A Decade of Successes, Challenges, and Opportunities , 2013, Science Translational Medicine.